Cambridge Investment Research Advisors, Inc. Biogen Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 3,432 shares of BIIB stock, worth $516,275. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,432
Previous 3,828
10.34%
Holding current value
$516,275
Previous $524,000
17.75%
% of portfolio
0.0%
Previous 0.0%
Shares
34 transactions
Others Institutions Holding BIIB
# of Institutions
1,031Shares Held
131MCall Options Held
2.84MPut Options Held
2.54M-
Vanguard Group Inc Valley Forge, PA17.3MShares$2.6 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$2.38 Billion1.62% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.19 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.47MShares$1.12 Billion0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.8MShares$722 Million0.11% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $21.7B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...